These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 29400127)

  • 1. Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.
    Balestrino R; Schapira AHV
    Neuroscientist; 2018 Oct; 24(5):540-559. PubMed ID: 29400127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocerebrosidase Mutations in Parkinson Disease.
    O'Regan G; deSouza RM; Balestrino R; Schapira AH
    J Parkinsons Dis; 2017; 7(3):411-422. PubMed ID: 28598856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocerebrosidase and Parkinson disease: Recent advances.
    Schapira AH
    Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GBA mutations and Parkinson's disease].
    Wang DX; Xie JX; Song N
    Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
    Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
    Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.
    Vieira SRL; Schapira AHV
    Free Radic Biol Med; 2021 Nov; 175():42-55. PubMed ID: 34450264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
    Beavan MS; Schapira AH
    Ann Med; 2013 Dec; 45(8):511-21. PubMed ID: 24219755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease.
    Pchelina S; Emelyanov A; Baydakova G; Andoskin P; Senkevich K; Nikolaev M; Miliukhina I; Yakimovskii A; Timofeeva A; Fedotova E; Abramycheva N; Usenko T; Kulabukhova D; Lavrinova A; Kopytova A; Garaeva L; Nuzhnyi E; Illarioshkin S; Zakharova E
    Neurosci Lett; 2017 Jan; 636():70-76. PubMed ID: 27780739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation.
    Galvagnion C; Marlet FR; Cerri S; Schapira AHV; Blandini F; Di Monte DA
    Brain; 2022 Apr; 145(3):1038-1051. PubMed ID: 35362022
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Smith L; Schapira AHV
    Cells; 2022 Apr; 11(8):. PubMed ID: 35455941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
    Barkhuizen M; Anderson DG; Grobler AF
    Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocerebrosidase and parkinsonism: lessons to learn.
    Marković I; Kresojević N; Kostić VS
    J Neurol; 2016 May; 263(5):1033-1044. PubMed ID: 26995357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.
    Gegg ME; Menozzi E; Schapira AHV
    Neurobiol Dis; 2022 May; 166():105663. PubMed ID: 35183702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
    Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
    Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.
    Taguchi YV; Liu J; Ruan J; Pacheco J; Zhang X; Abbasi J; Keutzer J; Mistry PK; Chandra SS
    J Neurosci; 2017 Oct; 37(40):9617-9631. PubMed ID: 28847804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations.
    Li H; Ham A; Ma TC; Kuo SH; Kanter E; Kim D; Ko HS; Quan Y; Sardi SP; Li A; Arancio O; Kang UJ; Sulzer D; Tang G
    Autophagy; 2019 Jan; 15(1):113-130. PubMed ID: 30160596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
    Tayebi N; Parisiadou L; Berhe B; Gonzalez AN; Serra-Vinardell J; Tamargo RJ; Maniwang E; Sorrentino Z; Fujiwara H; Grey RJ; Hassan S; Blech-Hermoni YN; Chen C; McGlinchey R; Makariou-Pikis C; Brooks M; Ginns EI; Ory DS; Giasson BI; Sidransky E
    Mol Genet Metab; 2017 Dec; 122(4):198-208. PubMed ID: 29173981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.